TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mortality rates at one- and two-year follow-ups
Endpoint domain: Mortality/survival
Primary endpoint: GHQ-28 anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: GHQ-28 depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients adhering to their new medicine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean time to correct response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean correct response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of coordination between spontaneous breathing and mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AUC0‐240 for plasma salbutamol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0‐240 for PEFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respirable fraction of particles < 5 microns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: midfoot height mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: foot mobility magnitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean plasma concentrations of d‐MPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ligament balancing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total activity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interactivity interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of low molecular weight heparins in preventing deep venous thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement of PEFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of tremor, nausea or vomiting, and palpitations
Endpoint domain: Adverse events/effects
Primary endpoint: Mean difference in Clinical Attachment Level (CAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference in depth of the intrabony defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recatheterization rate
Endpoint domain: Adverse events/effects
Primary endpoint: Alzheimer's Disease Assessment Scale‐Cognitive Subscale (ADAS‐Cog) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence of abnormal uterine bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Total self-reported sedentary time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation with total objective sedentary time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test-retest reliability of sedentary activities questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of genetic information on treatment decision-making
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Survival and risk for adverse late effects from cancer treatment
Endpoint domain: Mortality/survival
Primary endpoint: incidence of normoventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incidence of hypoventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Accuracy of pathology data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to progressive disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Stability Index of Biodex Balance System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in recommendations compared to experts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ETP (Endogenous Thrombin Potential)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of birth asphyxia
Endpoint domain: Mortality/survival
Primary endpoint: Asphyxia-related deaths in the delivery room
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in PHC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in MHC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delirium/coma-free days (DCFD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilator-free days (VFD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of dying at 28 days
Endpoint domain: Mortality/survival
Primary endpoint: Average number of progressively motile sperm per high power field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Demand for supplemental analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: onset time of complete akinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate of complete akinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropathic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: limitation of eye motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in total acne lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in cardioembolic strokes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: QALY decrements due to macrovascular complications
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: QALY decrements due to microvascular complications
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dorsal Lisfranc ligament length change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Tender-point threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma free fraction of L‐Trp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Amplitude of N1/P2 component
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in VAS of pain when taking the first steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days alive and out of hospital
Endpoint domain: Mortality/survival
Primary endpoint: Sum of completely anaesthetized innervation areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete motor block at the elbow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain on the 50 foot walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with slight pain or pain-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: measured blood loss from placental delivery to 2 h postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: frequency of calculated blood loss > 1000 mL
Endpoint domain: Adverse events/effects
Primary endpoint: Intraoperative time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean postoperative drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Milk vitamin B-6 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean excess weight loss (EWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean LDL cholesterol improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: quality of life (QOL) measures improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Childbirth experience rated as frightening
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Isovolumetric Systolic Ventricular Relaxation (ISVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vascular Endothelial Growth Factor (VEGF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: MICU mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Incisional hernia diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Surgical operation due to incisional hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Entering prison treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completing prison treatment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Community treatment entry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recovery rates from DIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-peptide responses to glucagon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum trough values > 10 mg/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in CGI-I scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in SDS scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: clustered metabolic risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: morphine equivalents dose at 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain scores on rest and movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: general psychiatric symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall level of functioning
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: travel anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: overnight SCAAT lipolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Eating self-regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment-emergent adverse events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: SHBG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Resistance to activated protein C (APCr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: blood products needed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: incidence of rhythm disturbances
Endpoint domain: Adverse events/effects
Primary endpoint: Between-subject variability (BV) of hemoglobin, RDW-CV and MCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in global health status/QoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of macular edema (ME)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mural coronary diameter reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood flow velocity (bAPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pharyngolaryngectomy-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Root coverage (RecRed)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Keratinized tissue (KT) width and thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final RES score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decreased risk of basal ganglia/thalamus injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: decreased risk of moderate-severe injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: increased proportion of normal imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CEFs
Endpoint domain: Adverse events/effects
Primary endpoint: Mean plasma glucose levels at 6 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Coronary revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aldosterone production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Postprandial changes of dipeptides and tripeptides in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical flexure endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean depression rating scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: healthy eating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abnormal GHQ12
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: WEMWBS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Palatability of bowel preparation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decrease in hot flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in menopausal symptom quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Treatment effect of spinal manipulation compared to placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Volumetric measurement of tumor burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: speed of processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neuropsychology performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: psychopathology severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dyspnea severity by transitional dyspnea index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DEXA t-score difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: F. nucleatum DNA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean Intraocular Pressure (IOP) on postoperative day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Intraocular Pressure (IOP) at 4-8 hours postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of IOP greater than 30 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life in cervical cancer patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: recurrent stroke within 90 days
Endpoint domain: Mortality/survival
Primary endpoint: Percentage change of body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: APP (Adenoma Per Polyp)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in mood symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clearance of antipyrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of hexobarbitone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of theophylline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean spatial variations in segmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: return of early continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical recurrence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic recurrence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic recurrence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness in the treatment of keloids and hypertrophic scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Community-wide reductions in fall injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: sPLA2‐IIA mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sPLA2 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients remaining asymptomatic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SSS score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Pulmonary artery mean pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: loss of reading speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slower renal function decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mortality through day 30
Endpoint domain: Mortality/survival
Primary endpoint: Composite endpoints of death, shock, or heart failure at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Composite endpoints of death, shock, or heart failure at 90 days
Endpoint domain: Mortality/survival
Primary endpoint: Physical functioning scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: NO(2)/NO(3) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: corneal haze score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: residual refractive error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine efficacy against RV-GE
Endpoint domain: Mortality/survival
Primary endpoint: MASI score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MelasQOL score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bioequivalence of repaglinide and metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluctuations in hunger
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in IL-1b levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in serum IL-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mortality risk associated with cognitive impairment
Endpoint domain: Mortality/survival
Primary endpoint: CD4(+) cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean dietary fat intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of reduction from baseline in mean 72-hour IEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean levels of exhaled nitric oxide (FeNO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy in the treatment of pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-operative nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of post-traumatic stress (PTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mycological cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Death, any recurrent myocardial infarction, or urgent target‐vessel revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of gastric volume and acid output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of patients discussing CHD risk reduction with their doctor
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Proportion of patients with a specific plan to reduce their CHD risk
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: decrease in laboratory utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rates of heart failure worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of hospitalizations for all causes
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Incidence of fatal and nonfatal cardiac events
Endpoint domain: Adverse events/effects
Primary endpoint: 60-meter sprint performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes